Trial
NCT04896658
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
Why stopped
The study was terminated due to FDA withdrawal of the drug and lack of enrollment with available BCMA therapies that were deemed safer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-03